Top 7 Antibody Discovery Companies Offering Antibody Discovery Platforms
.png)
Published: October 2025
In the cutting-edge field of biomedical science, the practice of antibody discovery underscores the importance of our body's immune response. Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins that serve as the vanguard of our immune system. They counteract foreign molecules or antigens that intrude into our body, ranging from viruses, fungi, and bacteria to non-living substances, such as toxins and chemicals. The intricacies of the antibody discovery process entail recognizing a unique region on an antigen, termed as an epitope, to which antibodies can bind and mediate an immune response. This opsonization process facilitates the phagocytosis of foreign substances, effectively neutralizing potential threats.
In recent times, there has been a palpable surge in the antibody discovery market, driven predominantly by the rising demand for antibody therapeutics. Consequently, the landscape of antibody discovery services has undergone significant changes with companies increasingly outsourcing to CMOs and CDMOs. These organizations, including notable antibody discovery companies like Myrio Therapeutics, have been deploying innovative antibody discovery platforms to accelerate workflow and offer specialized services. Their expertise ranges from antibody drug discovery services to more comprehensive antibody CRO services.
These advances are not only ensuring more efficient antibody solutions but also contributing to the growth and dynamism of the antibody discovery market. Further, antibody discovery companies like Mabsilico are employing computational approaches to revolutionize the antibody discovery platform. Their services are designed to expedite and streamline the antibody discovery process. Together with other leading players in the field, they are reshaping the future of antibody drug discovery services.
Looking ahead, the antibody discovery market is poised for significant growth. The market size is expected to expand to a 12% CAGR during the forecast period of 2023-2035. This growth is anticipated to be driven by the increasing demand for custom antibody services, including custom antibody development and antibody characterization services. The global market is set to witness this surge, with North America leading the charge due to its advanced healthcare infrastructure and high investment in research and development. Market report indicates that antibody discovery companies, including AlivaMab Discovery Services and Abveris are making substantial contributions to this growth through their innovative approaches to antibody discovery.
Roots Analysis has conducted an exhaustive study on Antibody Discovery Market featuring the current market landscape, market size and future opportunity for the antibody discovery companies, over a span of next 10 years.
As the antibody discovery market continues to expand, with North America as a prominent hub of antibody discovery services, the partnership between antibody drug developers and antibody discovery companies will play a pivotal role in catalyzing market growth and shaping the future of antibody discovery process for different types of antibodies, including, bispecific antibodies, antibody drug conjugates and other next-generation antibody therapeutics.
Top 7 Promising Antibody Discovery Companies Offering Antibody Discovery Platforms
- Ablexis
- Creative Biolabs
- Genmab
- Harbour BioMed
- Immunome
- Isogenica
- Ligand Pharmaceuticals
The figure below highlights the top seven antibody discovery companies offering antibody discovery platforms:
Interested in exploring 300 antibody discovery companies and their antibody discovery services and antibody discovery platforms?
Discover Below the Details on Top 7 Antibody Discovery Companies
Let us dive deep into the details of the top 7 antibody discovery companies. These companies were chosen based on Roots Analysis’ proprietary antibody discovery platforms competitiveness analysis, taking into consideration technology portfolio strength and recent initiatives. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Ablexis is Revolutionizing Antibody Discovery with AlivaMab Mouse Technology
1. Ablexis: Company Overview
Ablexis is US-based pharmaceutical company engaged in the generation of therapeutic antibody candidates with high potency, specificity, solubility and low immunogenicity risks, using its proprietary AlivaMab Mouse technology. As per the firm’s website, its platform allows for rapid discovery of high-quality therapeutic lead candidates over other antibody discovery platforms. In addition, it is worth highlighting that, the company has licensed its technology to several pharmaceutical and biotechnology companies.
| Key Parameters |
Specifications |
| Description | |
| Year of Establishment | 2009 |
| Number of Employees | 2-10 |
| Headquarters |  |
Antibody Discovery Platforms Portfolio
| Antibody Discovery Platforms | Method of Antibody Generation | Types of Antibodies Generated |
| AlivaMab Mouse | Transgenic Animal Based |
|
Recent Developments:
- In September 2025, Ablexis announced the launch of AlivaMab Mouse-NGX, representing the evolution of its Alivamab Mouse platform, that enables up to 6 fold production of antigen specific antibodies.
- In February 2023, Ablexis entered into a licensing agreement with Adimab in order to incorporate AlivaMab Mouse technology for antibody discovery process.
- Earlier, in November 2022, Ablexis and AlivaMab Discovery Services announced the expansion of capabilities related to antibody drug discovery and engineering. The expanded capabilities consist of diverse panels of high-quality antibodies that can be reformatted into multispecific formats as per partner’s choice. The panels include a large selection of CD3 antibodies that engage T-cells and eliminate cancer cells with minimal cytokine release.
To know more about the recent initiatives of Ablexis and other antibody discovery companies, access full report.
From Antigen Designing to Antibody Optimization, Creative Biolabs Offers Comprehensive Services
2. Creative Biolabs: Company Overview
Creative Biolabs is a biotechnology company engaged in the production and engineering of antibodies. The company utilizes its broad range of proprietary technologies, such as phage display platform, Hyperdoma, fully human antibody technology (FHAT), B-cell sorting platform, magic platform, Hi-affi human antibody discovery platform, multiple epitopes antigen designer (MEAD) and native antibody discovery platform for the generation of a large panel of antibodies. In addition, the company offers a wide array of services ranging from antigen designing to antibody optimization.
| Key Parameters |
Specifications |
| Description | |
| Year of Establishment | 2005 |
| Number of Employees | 51-200 |
| Headquarters |  |
Antibody Discovery Platforms Portfolio
| S. No. | Antibody Discovery Platforms | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | B-cell Sorting Platform | Single cell-based |
|
| 2 | Fully Human Antibody Technology | Transgenic Mouse |
|
| 3 | Hi-Affi human antibody platform | Others |
|
| 4 | Hyperdoma | Hybridoma Technology |
|
| 5 | Magic (Membrane Protein Production Platform) | Others |
|
| 6 | MEAD (Multiple Epitopes Antigen Designer) | Hybridoma Technology |
|
| 7 | Native Antibody Discovery Platform | Single cell-based |
|
| 8 | Phage Display Platform | Phage Display |
|
Recent Developments:
- The company in a press release stated that it aims to hit every major conference in the year 2025, in order to foster collaboration and knowledge exchange with the scientific community. In this context, the company participated / announced its participation across the following conferences:
- NIH Spring Research Vendor Fair, in Maryland, US (April 2025)
- 23rd BioPharma Drug Discovery Nexus Conference, in California, US (May 2025)
- World Bispecific Summit, in Massachusetts, US (September 2025)
- Exosome-Based Therapeutic Development Summit, in Massachusetts, US (October 2025)
- World ADC Summit, in California, US (November 2025)
- Antibody Engineering & Therapeutics, in California, US (December 2025)
To know more about the recent initiatives of Creative Biolabs and other antibody discovery companies, access full report.
Genmab is Specializing in Differentiated Antibody Therapeutics for Cancer
3. Genmab: Company Overview
Genmab is a biotechnology company that specializes in the discovery and development of differentiated antibody therapeutics for cancer. The company utilizes its proprietary platform for generation of large panels of antibodies. In addition, the company is engaged in building its own pipeline of molecules by innovative scientific approach, expertise in translational medicine laboratory and forming strategic partnerships.
| Key Parameters |
Specifications |
| Description | |
| Year of Establishment | 1999 |
| Number of Employees | 1,001-5,000 |
| Headquarters |  |
Antibody Discovery Platforms Portfolio
| Antibody Discovery Platforms | Method of Antibody Generation | Types of Antibodies Generated |
| Duobody | Others |
|
Recent Developments:
- In June 2025, Genmab announced the opening of a new site in New Jersey, expanding its presence in the region. The facility is expected to strengthen the company’s core competencies, foster collaboration across commercialization and R&D, and to make antibody therapies available to patients.
- Earlier, in May 2025, Genmab acquired ProfoundBio, a clinical stage biotechnology company developing next generation ADCs and ADC technologies for the treatment of cancer. This collaboration gives Genmab the rights to the latter’s ADC portfolio and allows combining of their antibody technologies, creating new opportunities for discovery and development of novel anti-cancer drugs.
To know more about the recent initiatives of Genmab and other antibody discovery companies, access full report.
Transgenic Mouse Platforms for Antibody Discovery is Driving Harbour BioMed's
4. Harbour BioMed: Company Overview
Harbour BioMed is a biotechnology company that specializes in the discovery and development of novel therapeutics for cancer, specifically in the field of immuno-oncology. Its business operations are based in Cambridge and its antibody platform segment is located in Rotterdam, Netherlands. The discovery and development programs of the company are centered on its two patented transgenic mouse platforms for the discovery of human antibodies. The company is involved in building its own pipeline of molecules through internal discovery and development efforts, forming collaborative alliances or through acquisitions of selective preclinical and clinical stage assets. Further, the company provides access to its platforms to other companies and academic institutes through its subsidiary, Harbour Antibodies.
| Key Parameters |
Specifications |
| Description | |
| Year of Establishment | 2016 |
| Number of Employees | 201-500 |
| Headquarters |  |
Antibody Discovery Platforms Portfolio
| S. No. | Antibody Discovery Platforms | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | Harbour Mice | Transgenic Animal Based |
|
| 2 | HBICE | Others |
|
| 3 | HCAbs platform | Transgenic Animal Based |
|
Recent Developments:
- In March 2025, Harbour BioMed entered into a strategic collaboration with AstraZeneca for the discovery and development of next generation therapeutic antibodies. The partnership also included an option to license Harbor’s proprietary Harbour Mice technology platform for its utilization across multiple therapeutic areas.
- Earlier, in February 2025, Harbour BioMed entered into a collaboration with Insilico Medicine to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective antibody discovery and artificial intelligence technologies.
To know more about the recent initiatives of Harbour BioMed and other antibody discovery companies, access full report.
Immunome’ Discovery Engine is being Utilized for Building a Rich Pipeline of Novel Antibodies
5. Immunome: Company Overview
Immunome is a biotechnology company that specializes in the discovery and development of novel antibody therapeutics, with a focus on oncology and infectious diseases. It is important to mention that the company is building a rich pipeline of novel antibodies through its Immunome Discovery Engine. In addition, the company examines human B cell to produce vast quantities of antibodies for functional based screening. The company claims that it has created over 250,000 hybridomas from cancer patients and patients suffering from a variety of malignancies and infectious diseases.
In June 2023, Immunome and Morphimmune announced a definitive merger agreement and a simultaneous private placement investment of USD 125 million to develop targeted cancer therapies. The combined company, operating as Immunome, possesses a synergistic platform to develop best-in-class targeted cancer therapies across multiple modalities.
| Key Parameters |
Specifications |
| Description | |
| Year of Establishment | 2008 |
| Number of Employees | 51-200 |
| Headquarters |  |
Antibody Discovery Platforms Portfolio
| S. No. | Antibody Discovery Platforms | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | RealMab |
|
|
| 2 | ScreenMab | NA | NA |
Recent Developments:
- In May 2025, the company announced participation in two investor conferences including:
- TD Cowen 6th Annual Oncology Innovation Summit
- Goldman Sachs 46th Annual Global Healthcare Conference
- Earlier, in April 2025, the company announced participation in the 24th Annual Needham Virtual Healthcare Conference, held virtually.
To know more about the recent initiatives of Immunome and other antibody discovery companies, access full report.
Isogenica is Utilizing Alexandria and LlamdA VHH Library for Antibody Generation
6. Isogenica: Company Overview
Isogenica is a biotechnology company that specializes in generation of biotherapeutics for the treatment of various diseases, such as cancer, inflammation, and other diseases. It is important to mention that the company utilizes its proprietary technologies, namely Alexandria and LlamdA VHH library or the generation of large panels of antibodies, such as single domain, monoclonal, bispecific antibodies and antibody drug conjugates. In addition, the company is involved in building its own pipeline of molecules by internal discovery and development efforts, partnering with global biopharmaceutical companies or through acquisitions of selective preclinical and clinical stage assets.
| Key Parameters |
Specifications |
| Description | |
| Year of Establishment | 2001 |
| Number of Employees | 11-50 |
| Headquarters |  |
Antibody Discovery Platforms Portfolio
| S. No. | Antibody Discovery Platforms | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | Alexandria | Phage Display Based |
|
| 2 | llamdA | Phage Display Based |
|
Recent Developments:
- In June 2025, Isogenica entered into an antibody discovery agreement with Cerberus Therapeutics to support the development of targeted immune-modulating therapies combining their platforms and expertise in antibody discovery.
- Earlier, in the same month, Isogenica entered into a collaboration with Charles River Laboratories in order to accelerate the discovery of next generation peptides and VHH antibodies.
To know more about the recent initiatives of Isogenica and other antibody discovery companies, access full report.
Ligand Pharmaceuticals Provides Innovations in Antibody Drug Discovery and Development with Proprietary Technologies and Acquisitions
7. Ligand Pharmaceuticals: Company Overview
Ligand Pharmaceuticals is a biopharmaceutical company that focuses on drug discovery, early-stage drug development and product reformulation. In addition to building its own pipeline of molecules, the company has acquired various technologies to develop new molecules and help other pharmaceutical companies in the discovery and development of proprietary therapeutic molecules; these include (in alphabetical order) Captisol technology, OmniAb technology, HepDirect, LTP technology and SURE technology platform.
| Key Parameters |
Specifications |
| Description | |
| Year of Establishment | 1987 |
| Number of Employees | 51-200 |
| Headquarters |  |
Antibody Discovery Platforms Portfolio
| Antibody Discovery Platforms | Method of Antibody Generation | Types of Antibodies Generated |
| OmniAb | Transgenic Animal Based |
|
Recent Developments:
- In May 2025, OmniAb, the spun-off antibody discovery business of Ligand Pharmaceuticals, entered into a co-discovery agreement with VERAXA Biotech for the development of a novel bispecific antibody utilizing OmniAb’s suite of transgenic antibody discovery solutions.
To know more about the recent initiatives of Ligand Pharmaceuticals and other antibody discovery companies, access full report.
What about other Antibody Discovery Companies Around the World?
The above article features seven antibody discovery companies selected from a pool of over 300 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
- https://www.bigcountryhomepage.com/business/press-releases/accesswire/1066742/ablexis-announces-validation-and-availability-of-alivamabr-mouse-ngx/
- https://www.24-7pressrelease.com/press-release/522021/creative-biolabs-rides-the-wave-of-therapies-for-a-booming-antibody-industry
- https://www.drugdiscoverytrends.com/as-some-biotechs-cut-genmab-unveils-striking-new-site-near-princeton/
- https://chemanager-online.com/en/news/genmab-completes-acquisition-of-profoundbio
- https://www.prnewswire.com/news-releases/harbour-biomed-enters-into-global-strategic-collaboration-with-astrazeneca-to-discover-and-develop-next-generation-therapeutic-antibodies-302407924.html
- https://www.contractpharma.com/breaking-news/harbour-biomed-insilico-partner-on-ai-driven-antibody-discovery/
- https://www.stocktitan.net/news/IMNM/immunome-to-present-at-upcoming-investor-mrvx0vwpzrlu.html
- https://www.stocktitan.net/news/IMNM/immunome-to-present-at-upcoming-investor-mrvx0vwpzrlu.html
- https://isogenica.com/cerberus-therapeutics-enters-into-antibody-discovery-agreement-with-isogenica/
- https://isogenica.com/isogenica-and-charles-river-peptide-vhh-discovery/
- https://www.contractpharma.com/breaking-news/veraxa-biotech-enters-co-discovery-alliance-with-omniab/